Health Claims

For HIV patients with belly fat and high liver enzymes, losing visceral fat improved liver enzymes whether they had hepatitis or not.

HIV patients with belly fat who took tesamorelin were more likely to lose at least 8% of their visceral fat than those who took a placebo.

HIV patients with belly fat and high liver enzymes had more visceral fat and less fat under the skin than those with normal liver enzymes.

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzymes.

In people with HIV and belly fat, higher amounts of visceral fat at the start were linked to higher liver enzyme levels.

For HIV patients with high liver enzymes taking a placebo, losing visceral fat didn't lead to better liver enzyme levels.

HIV patients with belly fat and high liver enzymes who lost at least 8% visceral fat were more likely to have their ALT levels return to normal after 6 months than those who didn't lose that much fat.

HIV patients with high liver enzymes who lost visceral fat from tesamorelin kept their liver enzyme improvements for a full year even after stopping the drug, even though some fat came back.

HIV patients with belly fat and high liver enzymes who lose at least 8% of visceral fat see a bigger drop in AST levels than those who don't lose that much fat.

For people with HIV and belly fat who have high liver enzyme levels, those who lose at least 8% of their visceral fat see a bigger drop in ALT levels than those who don't lose that much fat.

HIV patients on medication who keep taking tesamorelin for a year continue to have less belly fat, lower triglycerides, and better cholesterol levels compared to when they started. This finding is from the abstract summary - full study details were not available

People with HIV on medication who take tesamorelin feel better about their belly appearance, as both they and their doctors report improvements. This finding is from the abstract summary - full study details were not available

Tesamorelin improves the ratio of bad cholesterol to good cholesterol by about 7% in HIV patients on medication, which is better for heart health. This finding is from the abstract summary - full study details were not available

Tesamorelin helps lower triglycerides, a type of fat in the blood, by about 12% in HIV patients on medication compared to those not taking it. This finding is from the abstract summary - full study details were not available

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher IGF-1 levels, a hormone involved in growth and metabolism, suggesting broader metabolic benefits.

HIV patients on tesamorelin with denser under-the-skin fat had lower total cholesterol, a key indicator of heart health, suggesting better fat quality may improve cardiovascular risk factors.

Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher levels of the metabolism-regulating hormone adiponectin, suggesting improved fat function.

When HIV patients on tesamorelin had denser belly fat, their bodies also produced more adiponectin, a hormone that helps regulate metabolism, showing a link between fat quality and metabolic health.

The same HIV patients with belly fat who responded to tesamorelin also saw their under-the-skin fat become denser by 3.5 points on CT scans after 26 weeks, regardless of fat amount changes, indicating healthier fat tissue.

For HIV patients with excess belly fat who responded to the drug tesamorelin, taking the drug for 26 weeks made the fat around their organs denser by 2.3 points on a CT scan scale, even after accounting for changes in fat amount, which suggests the fat became healthier.

Tesamorelin reduced belly fat without affecting other fat or weight in HIV patients with abdominal obesity.

Even after accounting for other factors like sex and hepatitis, higher visceral fat was still linked to higher ALT levels in HIV patients with high liver enzymes.

HIV patients with belly fat and high liver enzymes had more visceral fat (191 vs. 167 cm²) than those with normal liver enzymes, showing a clear link.